| Literature DB >> 33716922 |
Roberta Scalise1,2, Giuseppina Sgandurra1,3, Valentina Menici1, Nicola Capodagli1,3, Roberta Di Pietro1, Domenico M Romeo4, Francesca Sini4, Emanuela Pagliano5, Maria Foscan5, Giovanni Cioni1,3, Roberta Battini1,3.
Abstract
Tetrabenazine has been studied with a variety of hyperkinetic movement disorders, but there is limited and empirical literature on the potential efficacy of tetrabenazine in children with dyskinetic cerebral palsy (DCP). The purpose of this study was to evaluate the efficacy of tetrabenazine in a sample of children with DCP using the Movement Disorders-Childhood Rating Scale 4-18 Revised (MD-CRS 4-18 R). The study is a multicenter retrospective longitudinal study in which the participants were selected from the databases of each Center involved, according to detailed inclusion criteria. The study was performed on 23 children and adolescents (19 male and 4 females; mean age 8.28 years, SD 3.59) with DCP having been evaluated before starting the treatment (baseline), after 6 and 12 months of treatment and in a sub-cohort after >2 years follow-up. A linear mixed model was used to evaluate the effects of the different timings on each MD-CRS 4-18 R Index (Index I, Index II, and Global Index) adding age and type of movement disorder as random effect. A significant clinical improvement related to a reduction of MD-CRS 4-18 R Indexes was detected between the baseline and after 6 and 12 months of treatment. Findings support the efficacy of tetrabenazine in children with DCP through a standardized outcome measure (MD-CRS 4-18 R) and confirm the use of this scale as a suitable tool to detect changes in further randomized clinical trials.Entities:
Keywords: MD-CRS 4–18 R; children; dyskinetic cerebral palsy; movement disorder; tetrabenazine
Year: 2021 PMID: 33716922 PMCID: PMC7953156 DOI: 10.3389/fneur.2021.612429
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003